Oxford Biomedica signs new Covid vaccine deal with AstraZeneca

Oxford Biomedica

403.00p

15:35 15/11/24

-2.30%

-9.50p

Oxford Biomedica has signed a new three-year deal to make AstraZeneca’s Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.

AstraZeneca

9,990.00p

15:45 15/11/24

-2.93%

-302.00p

FTSE 100

8,060.61

15:45 15/11/24

n/a

FTSE 350

4,453.56

15:45 15/11/24

n/a

FTSE All-Share

4,411.85

15:45 15/11/24

n/a

FTSE Small Cap

6,802.32

15:45 15/11/24

n/a

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

The Oxford-based gene and cell therapy group said it expected to record about £30m in revenue from the contract in the current financial year.

Under the new deal, manufacturing of vaccines at Oxford manufacturing facility, Oxbox, will be available to AstraZeneca on an as-needed basis beyond 2022.